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Research
AbstrACt
Objectives To examine the knowledge and attitudes of 
Australian general practitioners (GP) towards medicinal 
cannabis, including patient demand, GP perceptions 
of therapeutic effects and potential harms, perceived 
knowledge and willingness to prescribe.
Design, setting and participants A cross-sectional 
survey completed by 640 GPs (response rate=37%) 
attending multiple-topic educational seminars in five major 
Australian cities between August and November 2017.
Main outcome measures Number of patients enquiring 
about medicinal cannabis, perceived knowledge of 
GPs, conditions where GPs perceived it to be beneficial, 
willingness to prescribe, preferred models of access, 
perceived adverse effects and safety relative to other 
prescription drugs.
results The majority of GPs (61.5%) reported one or 
more patient enquiries about medicinal cannabis in the 
last three months. Most felt that their own knowledge 
was inadequate and only 28.8% felt comfortable 
discussing medicinal cannabis with patients. Over half 
(56.5%) supported availability on prescription, with the 
preferred access model involving trained GPs prescribing 
independently of specialists. Support for use of medicinal 
cannabis was condition-specific, with strong support for 
use in cancer pain, palliative care and epilepsy, and much 
lower support for use in depression and anxiety.
Conclusions The majority of GPs are supportive or neutral 
with regards to medicinal cannabis use. Our results 
highlight the need for improved training of GPs around 
medicinal cannabis, and the discrepancy between GP-
preferred models of access and the current specialist-led 
models.
IntrODuCtIOn 
There is strong and increasing public support 
for the use of medicinal cannabis in Australia.1 
This support has been a driver of a number 
of legislative and policy changes enacted over 
the last two years. These changes have allowed 
approved companies to cultivate cannabis 
plants and manufacture cannabis products, 
and have facilitated legal access to medicinal 
cannabis for approved patients.2 
Despite this, patient access remains complex 
and highly restricted. Doctors wishing to 
prescribe medicinal cannabis products must 
either apply to become authorised prescribers 
for a class of patients, or apply for access for 
individual patients under the ‘Special Access 
Scheme Category B (SAS-B)’3 via the Thera-
peutic Goods Administration (TGA), a regu-
latory body for therapeutic goods in Australia. 
Parallel approvals may also be required from 
the relevant State or Territory Department 
of Health. Even with these approvals in 
place, patients often find available products 
prohibitively expensive. Moreover, few formal 
educational training programmes for doctors 
on the topic of medicinal cannabis have been 
initiated since the recent legislative changes.
Consequently, few doctors and patients are 
accessing medicinal cannabis in Australia. 
Currently, there are only about 33 authorised 
prescribers, servicing around 190 patients, 
with a further 513 patients granted access 
via SAS-B approvals (TGA, personal commu-
nication, May 2018). This contrasts with the 
more mature access schemes of countries 
such as Canada, where approximately 200 000 
patients are serviced.4
Under current schemes, Australian 
general practitioners (GP) are typically only 
permitted to prescribe medicinal cannabis if 
supported by a specialist.3 Nonetheless, GPs 
are generally the first point of contact for 
strengths and limitations of this study
 ► This is the first study to have examined the attitudes 
and knowledge of Australian general practitioners 
(GP) about medicinal cannabis.
 ► The study was performed across five major cities 
in Australia and included a relatively large sample 
(n=640) of GPs.
 ► Limitations include utilising a survey without es-
tablished psychometric properties and exclusive 
recruitment of self-selected GPs from educational 
seminars who were motivated to complete a survey 
on medicinal cannabis.
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patients enquiring about, or seeking access to, medicinal 
cannabis. Australian medical bodies have forecasted that 
patient demand for medicinal cannabis is set to increase.5 
With ongoing media coverage fuelling patient expecta-
tions regarding therapeutic efficacy and cannabis access,6 
GPs may be forced into the role of gatekeepers despite 
having limited knowledge and training in the field.
The attitudes of Australian GPs towards medicinal 
cannabis are unknown. Statements from peak medical 
bodies such as the Royal Australasian College of Physi-
cians,7 Australian Medical Association, and the Austra-
lian and New Zealand College of Anaesthetists’ Faculty of 
Pain Management generally advise caution on the basis 
of limited evidence for efficacy and safety.5 8–10 Surveys 
from other countries suggest that clinicians are gener-
ally more reticent towards medicinal cannabis than the 
general public, particularly in the USA,11 12 with concerns 
centred on limited evidence for efficacy and adverse 
effects, including abuse and dependence.11–13 Neverthe-
less, recent analyses suggest that the majority of GPs and 
specialists internationally support the use of medicinal 
cannabis for specific conditions.14
This article describes the results of a survey of Austra-
lian GPs around medicinal cannabis issues, including 
their clinical experiences, perceived knowledge, and 
beliefs about its regulation, safety, indications for use and 
the preferred role of GPs in its prescription.
MethODs
Printed surveys were distributed at one-day general prac-
tice educational seminars held in five major Australian 
cities (Sydney, Melbourne, Brisbane, Adelaide and Perth) 
between August and November 2017. All GPs and GP 
registrars were eligible to participate (n=1728). Seminars 
covered a range of topics relevant to general practice 
with around 18 different topics covered on the day in 
consecutive 20–30 min presentations. GPs and GP regis-
trars received professional education points for attending 
the seminars. One of the authors (ISM) spoke on the 
topic of medicinal cannabis at each event, but surveys 
were completed and collected prior to this presentation. 
During the opening of each HealthEd seminar, participants 
were informed that the survey and its information and 
consent form were located in their conference satchel. 
Participants were instructed to turn in their surveys, 
before afternoon tea, into drop boxes at the conference.
The survey was devised specifically for use in this study, 
and thus had not been psychometrically validated. Ques-
tions were reviewed by an advisory group of GPs to ensure 
appropriate wording and clarity (see online supplemen-
tary material for copy of full survey). Participants first 
completed a series of closed questions on demographics, 
vocational experience (years in practice, registrar status, 
hours per week) and practice characteristics (size, 
state/territory, geographical classification). The survey 
proper consisted of 46 items on topics related to medic-
inal cannabis including clinical experience (4 items); 
perceived knowledge (5 items); concerns and awareness 
about safety and efficacy (18 items); appropriate indica-
tions for use (14 items); and views on the role of GPs and 
specialists in its prescribing (5 items).
Participants rated the extent to which they agreed 
with 44 statements on a 5-point Likert scale (1=strongly 
disagree; 5=strongly agree). There were also two multi-
ple-choice questions concerning patient demand and 
prescribing preferences (role of GPs/specialists). The 
latter question was only introduced after the first seminar 
(included in 73% of completed surveys; excludes respon-
dents from the Sydney event). A space for open-ended 
comments was provided at the end of the survey. 
Results were summarised using descriptive statistics 
(frequency, percentage of valid responses). Likert scale 
responses were generally collapsed into three catego-
ries: agree, neutral and disagree. Open-ended comments 
were reviewed for common themes. A composite score 
for Perceived Knowledge was created by summing scores 
from five knowledge-related questions. Age, sex and 
perceived knowledge were tested as potential predictors 
of views on medicinal cannabis availability (‘medicinal 
cannabis should currently be available on prescription 
for certain indications’; 1=strongly disagree to 5=strongly 
agree) using separate ordinal logistic regression analyses. 
Χ2 tests were used to compare the demographic charac-
teristics of our sample to the Australian population of 
GPs.15
One section of the questionnaire asked whether GPs 
support the use of medicinal cannabis in 14 different 
medical conditions. To assess whether their support was 
consistent with current evidence for efficacy, each indi-
cation was categorised as having either ‘Good Evidence 
for Efficacy’ (spasticity in multiple sclerosis (MS), intrac-
table epilepsy, chronic cancer pain, chronic non-cancer 
pain, neuropathic pain, chemotherapy-induced nausea 
and vomiting (CINV)) or ‘Poor Evidence for Efficacy’ 
(anxiety, depression, post-traumatic stress disorder, 
cachexia, cancer/antitumour effects, agitation in 
dementia and insomnia) based on two recent authorita-
tive reviews,16 17 and levels of support expressed compared 
with this evidence base. The evidence for ‘palliative care’ 
was not assessed in either review and was thus excluded 
for the purposes of this analysis. Further, GP respondents 
were categorised as having either ‘Good Perceived Knowl-
edge’ or ‘Poor Perceived Knowledge’ using a cut-off score 
of 15 on the composite score for Perceived Knowledge 
(the midpoint between the lowest (=5) and highest 
(=25) possible scores for the five questions relating to 
self-knowledge). Χ2 tests were used to assess whether 
GPs with Good Perceived Knowledge expressed greater 
support for specific indications than those with Poor 
Perceived Knowledge. Bonferroni correction was used to 
control for these multiple comparisons.
Analyses were conducted using IBM SPSS Statistics for 
Windows, V.24.0 (IBM), and graphs were created using 
GraphPad Prism V.7.02 for Windows (GraphPad Soft-
ware, La Jolla, California, USA).
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Patient and public involvement
Patients were not involved in this study.
results
Demographic data
Demographic and practice details of the 640 participants 
are shown in table 1. The majority of participants were 
female (67.3%), aged between 35 and 64 years (77.5%), 
and residing in Victoria (30.3%) and New South Wales 
(27.5%). Over half of respondents had been practising 
for >15 years (56.7%), worked >30 hours/week (63.4%) 
and serviced metropolitan areas (60.3%). Only 8.2% 
were in single-GP practices and 7.9% were registrars.
experience, practice and general attitudes
A majority of GPs (61.5%) had experienced at least one 
patient enquiry regarding medicinal cannabis in the prior 
3 months, with 7.5% reporting more than five enquiries. 
When considering GPs working >30 hours/week, the 
proportion with at least one enquiry increased to 69.0% 
and 11.8% received more than five enquiries (table 2).
More than half of GPs agreed with the statement 
that medicinal cannabis should currently be available 
on prescription for certain indications (strongly agree: 
19.6%, n=125/637; slightly agree: 36.9%), while 14.9% 
disagreed (figure 1). GPs were more likely to agree if 
they were older (χ2(4)=25.63, p<0.001) and had greater 
Table 1 Demographic and practice characteristics of GPs in this study, and all GPs in Australia
GP survey (n=640) Australia (n=34 606)15
P values (X2 test)n Valid % %
Age (n=640) <0.001
  <35 57 8.9 13.4
  35–44 134 20.9 24.9
  45–54 177 27.7 24.9
  55–64 185 28.9 23.1
  65+ 87 13.6 13.7
Sex (n=636) <0.001
  Female 428 67.3 44.7
GP registrar (n=611) 0.08
  Yes 48 7.9 10.0
State/territory (n=627) 0.001
  New South Wales 175 27.9 30.6
  Victoria 193 30.8 24.1
  Queensland 129 20.6 21.7
  South Australia 81 12.9 7.8
  Western Australia 39 6.2 10.2
Geographical area (n=611)
  Metropolitan 381 62.4 68.2 0.01
  Regional 206 33.7 28.0
  Remote 24 3.9 3.9
Years as GP (n=637)
  <2 38 6.0
  2–5 90 14.1
  6–15 148 23.2
  16–25 136 21.4
  26+ 225 35.3
GP, general practitioner.
Table 2 Reported number of patient enquiries about 
medicinal cannabis in the prior 3 months, for all respondents 
and those working over 30 hours/week, on average
Number of 
patients 
enquiring
All respondents 
(n=615)
Respondents 
>30 hours/week (n=391)
n (%) n (%)
0 237 (38.5) 116 (31.0)
1 159 (25.9) 90 (24.1)
2–5 173 (28.1) 124 (33.2)
6–10 33 (5.4) 32 (8.6)
>10 13 (2.1) 12 (3.2)
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perceived knowledge (χ2(2)=5.54, p=0.02), but there was 
no difference between sexes (χ2(1)=2.55, p=0.11).
More GPs agreed that they had patients who would 
benefit from medicinal cannabis (44.0%, n=280/636) 
than disagreed (21.4%), with 34.6% expressing a neutral 
opinion (figure 1). Conversely, fewer respondents agreed 
that they would like to be able to prescribe medicinal 
cannabis (28.9%, n=183/633) than disagreed (33.8%), 
again with a high number of neutral responses. Approx-
imately half of respondents (n=51.9%; n=328/632) did 
not feel comfortable discussing medicinal cannabis with 
their patients.
Perceived knowledge
GPs generally rated their knowledge of medicinal 
cannabis as poor (figure 2). On all five knowledge-related 
items, over two-thirds of respondents disagreed that they 
had knowledge of the topic in question. Notably, 65.4% 
(n=417/638) ‘strongly disagreed’ that they knew how to 
access medicinal cannabis for patients, and more than 
half ‘strongly disagreed’ that they knew about available 
products (55.5%, n=354/638) or the current regulatory 
approach (57.8%, n=370/630). According to their own 
self-ratings, 543 (86%) GPs had Poor Perceived Knowl-
edge (<15/25 composite score) while 88 (14%) GPs 
were categorised as having Good Perceived Knowledge 
(≥15/25 composite score).
Respondents were more likely to endorse an access 
model permitting prescribing by trained and accredited 
GPs (78.6% agree, n=503/640), or by GPs in a ‘shared 
care’ arrangement with a specialist (63.2%, n=401/634) 
than specialist-only prescribing (44.6%, n=283/634). 
When asked to choose one preferred model, 41.2% 
(n=164/398; note this question was not included in the 
survey used at the first seminar in Sydney) indicated 
trained GPs as their preferred prescriber, followed by 
shared care (29.6%). Specialist-only prescribing was 
preferred by 14.6% of respondents, while only 12.1% 
preferred that all GPs have the right to prescribe, regard-
less of training.
Indications for use and evidence for efficacy
Almost half of respondents (48.0%, n=305/635) were 
neutral as to whether there was sufficient overall scien-
tific evidence for the efficacy of medicinal cannabis, with 
22.8% supporting the statement. Those who agreed that 
medicinal cannabis should be available on prescription 
had higher endorsement of the statement than those 
who disagreed (40.2% vs 11.7%). GPs supported the use 
of medicinal cannabis in chronic cancer pain (80.2% 
agree, n=506/631), palliative care (78.8%, n=494/627) 
and intractable epilepsy (70.3%, n=441/627; figure 3). 
Use in chronic non-cancer pain and neuropathic pain 
was endorsed by only 39.1% (n=246/629), and 38.3% 
Figure 1 Attitudes and clinical experiences of general practitioners with respect to medicinal cannabis, n=632–637, valid 
percentage. 
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(n=241/630) of respondents, respectively, with a high 
degree of neutrality. Less than 15% of GPs supported use 
in anxiety, insomnia or depression with a majority of GPs 
declining to support use in these conditions (figure 3).
GPs with Good Perceived Knowledge of medicinal 
cannabis were more likely to support its use in neuro-
pathic pain (52.9%) and chronic non-cancer pain (54%) 
than GPs with Poor Perceived Knowledge (35.6% and 
36.4%, respectively) (neuropathic pain, X2(2, n=620)=9.9, 
p=0.007; chronic non-cancer pain, X2(2, n=620)=11.2, 
p=0.004). No other significant differences between GPs’ 
perceived knowledge level and their support for specific 
medical conditions were identified.
Perceived features and adverse effects of medicinal cannabis
Approximately two-thirds of respondents disagreed 
with the statement that medicinal cannabis was no 
different from street cannabis (43.9% strongly disagree; 
n=271/640; 20.5% slightly disagree), while 14.4% agreed.
The side effects of medicinal cannabis endorsed by 
more than half of respondents included driving impair-
ment (64.9% agree, n=408/629), adverse effects on the 
developing brain (58.4%, n=366/627), cognitive impair-
ment (56.5%, n=356/630) and addiction and depen-
dence (56.3%, n=353/627); psychosis was endorsed by 
49.9% (n=313/627).
Overall, 27.7% of respondents (n=177/637) agreed that 
they would not prescribe medicinal cannabis due to the 
risk of abuse and dependence, and 19.8% (n=127/638) 
due to other side effects. These proportions were higher 
among GPs who disagreed with the availability of medic-
inal cannabis on prescription (58.1% and 44.2%, respec-
tively) and among those who disagreed that they would 
like to prescribe medicinal cannabis (47.6% and 34.6%, 
respectively).
A high proportion of GPs were neutral with respect to 
whether medicinal cannabis was more hazardous than 
other prescription medicines (range: 43.7%–51.3%; 
figure 4). Of the remaining responses, a majority believed 
that medicinal cannabis was safer than chemotherapy 
drugs (78.1%, n=278/356), opioid analgesics (75.6%, 
n=248/328), benzodiazepines (74.5%, n=248/333) and 
antipsychotics (68.3%, n=209/306), and over 50% for 
antidepressants and statins.
Open-ended responses
Of the 156 open-ended responses, 48.1% concerned 
the participant’s lack of knowledge about medicinal 
cannabis and/or the desire for training. Other common 
themes included the need for more evidence of effi-
cacy (n=18) and concerns about harms (n=19), namely 
abuse and dependence (n=10), cannabis-seeking for 
recreational use (n=5), repeating mistakes made with 
opioids/benzodiazepines (n=6) and other side effects 
(n=4).
Figure 2 Ratings of general practitioners on knowledge-related items, n=636–640, valid percentage. RACGP, Royal Australian 
College of General Practitioners.
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DIsCussIOn
To our knowledge, this is the first study of the experiences, 
attitudes and knowledge of Australian GPs regarding medic-
inal cannabis. The survey demonstrates that many GPs have 
fielded recent enquiries about medicinal cannabis from 
their patients, yet half were not comfortable dealing these 
enquiries and most felt poorly informed about medicinal 
cannabis and its current availability, regulation and uses. 
This perceived lack of knowledge was strongly conveyed in 
the open-ended comments, as well as broadly reflected in the 
large number of neutral responses to questions regarding 
therapeutic and adverse effects.
In agreement with clinician surveys in the USA,11 12 
Australian GPs were somewhat conservative in their atti-
tudes about medicinal cannabis: slightly less than 60% 
agreed that medicinal cannabis should be available on 
prescription compared with approximately 85% of the 
general Australian population.1 This rate, however, has 
somewhat risen since previous surveys, with just under 
30% of Australian GPs reporting that cannabis should be 
available for medicinal purposes in 201218. This suggests a 
possible shift in attitudes over time as increasing commu-
nity support has driven a number of legislative and policy 
changes for greater patient access and clinical trials in 
Australia. In the present survey, GPs were generally more 
supportive of use of medicinal cannabis in conditions 
with a stronger evidence base (such as spasticity in MS, 
CINV) and/or where few effective alternatives exist (palli-
ative care, cancer pain, intractable epilepsy).16 This also 
aligns with the indications for use suggested by various 
state governments.19 20 By contrast, less than 40% of all 
GPs supported use of medicinal cannabis in chronic 
non-cancer pain. This may reflect the mixed findings 
regarding efficacy for this indication,16 21 concerns about 
inappropriate use, particularly in light of the problems 
associated with prescription opioids,22 and the lack of 
endorsement by Australian government and medical 
organisations.10 19 Similarly, concerns about limited 
evidence for efficacy, risk of worsening illness and inap-
propriate use may underlie the very low support for use in 
depression, anxiety and insomnia.16 19 It is somewhat trou-
bling that these latter indications were among the most 
Figure 3 Support for use of medicinal cannabis in different conditions, n=627–632, valid percentage. CINV, chemotherapy-
induced nausea and vomiting; MS, multiple sclerosis; PTSD, post-traumatic stress disorder.
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common reasons for illegal use of cannabis for medicinal 
purposes in a survey of more than 1700 current users in 
the Australian community (Lintzeris et al, in press).
Although GPs exhibited responses that suggested at 
least some familiarity with the scientific and clinical liter-
ature, perceived knowledge about the effects, products 
and process of accessing medicinal cannabis was gener-
ally very low. Less than 10% of GPs in our survey reported 
understanding the current regulations concerning 
medicinal cannabis or how it can be accessed for patients. 
It is well known that poor knowledge and low levels of 
comfort discussing issues with patients are barriers to 
optimal patient care.12 23 Provision of continuing medical 
education and guidelines on the regulatory, pharmaco-
logical and clinical aspects of medicinal cannabis are vital 
for equipping GPs to manage patients effectively.
One surprising aspect of this survey was how GPs rated 
medicinal cannabis relative to other common classes of 
prescription medicines. Of those expressing a non-neu-
tral opinion (approximately 50%), about three-quarters 
rated medicinal cannabis as less harmful than opioids 
and benzodiazepines, and notably, just over half rated 
it less harmful than antidepressants and statins. This 
perception of the relative safety of medicinal cannabis 
compared with opioids and benzodiazepines may 
reflect its negligible rate of mortality and relatively mild 
dependence and withdrawal syndrome.24 Nonethe-
less, cannabis can clearly produce dependence; recent 
estimates suggest that there are over 45 000 treatment 
episodes each year for Australians seeking control over 
their cannabis use.25 Concerns about abuse, misuse 
and dependence were an identified theme of the open-
ended comments in our survey. Moreover, almost half 
of the GPs who did not want to be able to prescribe 
cannabis cited the risk of abuse and dependence as a 
primary concern.
Although there was a high degree of neutrality 
with respect to the desire of GPs to prescribe medic-
inal cannabis, the vast majority supported a model of 
prescribing in which GPs played a significant role. A 
model in which trained, accredited GPs could prescribe 
without specialist input received the strongest support, 
followed by GP prescribing in a ‘shared care’ arrange-
ment with a specialist. This contrasts with the current 
model in Australia, where prescribing is conducted by 
specialists, although shared care arrangements are theo-
retically possible.3 Although specialist-only prescribing 
may provide greater restrictions on use, the extension 
of prescribing rights to appropriately trained GPs argu-
ably enables more holistic patient care, more frequent 
monitoring, better detection of adverse effects and more 
timely treatment.26 It is notable that GPs are empowered 
to prescribe, or permit access to, medicinal cannabis 
products in countries such as Canada and the USA,12 23 27 
and the Royal Australian College of General Practitioners 
Figure 4 Ratings of relative hazards of medicinal cannabis compared with other prescription medicines, n=627–632, valid 
percentage.
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recently updated their position statement to explic-
itly endorse a direct role for GPs in medicinal cannabis 
access.28
The strength of the study is the unique nature of 
the survey and the relatively large sample size enabled 
by accessing the GPs attending popular educational 
events. While our response rate of 37% appears rela-
tively low, it exceeds typical published response rates of 
GP surveys.29 Limitations include the sole recruitment 
of self-selected GPs from HealthEd seminars, reliance 
on self-report of service provision and utilising a survey 
without established psychometric properties. Further-
more, the survey respondents differed on a number of 
demographic and practice characteristics to the general 
population of GPs in Australia, suggestive of a non-rep-
resentative sample. For instance, there was a dispropor-
tionate representation of female GPs in our study, which 
may be due to a tendency for greater survey response 
from women relative to men in general.30 Finally, the 
findings cannot be generalised to other countries such 
as the USA and Canada, among others, where access to 
medicinal cannabis is not so strictly regulated.
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